Nature Communications (Sep 2017)
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis
- Sara Trabanelli,
- Mathieu F. Chevalier,
- Amaia Martinez-Usatorre,
- Alejandra Gomez-Cadena,
- Bérengère Salomé,
- Mariangela Lecciso,
- Valentina Salvestrini,
- Grégory Verdeil,
- Julien Racle,
- Cristina Papayannidis,
- Hideaki Morita,
- Irene Pizzitola,
- Camille Grandclément,
- Perrine Bohner,
- Elena Bruni,
- Mukul Girotra,
- Rani Pallavi,
- Paolo Falvo,
- Elisabeth Oppliger Leibundgut,
- Gabriela M. Baerlocher,
- Carmelo Carlo-Stella,
- Daniela Taurino,
- Armando Santoro,
- Orietta Spinelli,
- Alessandro Rambaldi,
- Emanuela Giarin,
- Giuseppe Basso,
- Cristina Tresoldi,
- Fabio Ciceri,
- David Gfeller,
- Cezmi A. Akdis,
- Luca Mazzarella,
- Saverio Minucci,
- Pier Giuseppe Pelicci,
- Emanuela Marcenaro,
- Andrew N. J. McKenzie,
- Dominique Vanhecke,
- George Coukos,
- Domenico Mavilio,
- Antonio Curti,
- Laurent Derré,
- Camilla Jandus
Affiliations
- Sara Trabanelli
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Mathieu F. Chevalier
- Urology Research Unit, Lausanne University Hospital (CHUV)
- Amaia Martinez-Usatorre
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Alejandra Gomez-Cadena
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Bérengère Salomé
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Mariangela Lecciso
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology “Seràgnoli”, University of Bologna
- Valentina Salvestrini
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology “Seràgnoli”, University of Bologna
- Grégory Verdeil
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Julien Racle
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Cristina Papayannidis
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology “Seràgnoli”, University of Bologna
- Hideaki Morita
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich
- Irene Pizzitola
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Camille Grandclément
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Perrine Bohner
- Urology Research Unit, Lausanne University Hospital (CHUV)
- Elena Bruni
- Department of Medical Biotechnologies and Translational Medicine, University of Milan
- Mukul Girotra
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Rani Pallavi
- Department of Experimental Oncology, European Institute of Oncology
- Paolo Falvo
- Department of Experimental Oncology, European Institute of Oncology
- Elisabeth Oppliger Leibundgut
- Department of Hematology, Bern University Hospital, University of Bern
- Gabriela M. Baerlocher
- Department of Hematology, Bern University Hospital, University of Bern
- Carmelo Carlo-Stella
- Humanitas Cancer Center, Humanitas Clinical and Research Center
- Daniela Taurino
- Humanitas Cancer Center, Humanitas Clinical and Research Center
- Armando Santoro
- Humanitas Cancer Center, Humanitas Clinical and Research Center
- Orietta Spinelli
- Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII
- Alessandro Rambaldi
- Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII
- Emanuela Giarin
- Dipartimento per la Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, University of Padova
- Giuseppe Basso
- Dipartimento per la Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, University of Padova
- Cristina Tresoldi
- Immunoematologia e Medicina Trasfusionale, Laboratorio Ematologia Molecolare, Biobanca Neoplasie Ematologiche, San Raffaele Hospital
- Fabio Ciceri
- Divisione di Ricerca di Medicina Rigenerativa, Terapia Cellulare e Genica IRCCS, San Raffaele Hospital
- David Gfeller
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Cezmi A. Akdis
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich
- Luca Mazzarella
- Department of Experimental Oncology, European Institute of Oncology
- Saverio Minucci
- Department of Experimental Oncology, European Institute of Oncology
- Pier Giuseppe Pelicci
- Department of Experimental Oncology, European Institute of Oncology
- Emanuela Marcenaro
- Department of Experimental Medicine (DI.ME.S.)-Section of Histology, and Center of Excellent of Biomedical Research (CEBR), University of Genoa
- Andrew N. J. McKenzie
- MRC Laboratory of Molecular Biology
- Dominique Vanhecke
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- George Coukos
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- Domenico Mavilio
- Department of Medical Biotechnologies and Translational Medicine, University of Milan
- Antonio Curti
- Department of Specialistic, Diagnostic and Experimental Medicine, Institute of Hematology “Seràgnoli”, University of Bologna
- Laurent Derré
- Urology Research Unit, Lausanne University Hospital (CHUV)
- Camilla Jandus
- Ludwig Institute for Cancer Research, Department of Fundamental Oncology, University of Lausanne
- DOI
- https://doi.org/10.1038/s41467-017-00678-2
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 14
Abstract
Group 2 innate lymphoid cells (ILC2s) modulate inflammatory and allergic responses, but their function in cancer immunity is still unclear. Here the authors show that, in acute promyelocytic leukaemia, tumour-activated ILC2s secrete IL-13 to induce myeloid-derived suppressor cells and support tumour growth.
